Cyclopharm Ltd
ASX:CYC
Cyclopharm Ltd
Revenue
Cyclopharm Ltd
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
C
|
Cyclopharm Ltd
ASX:CYC
|
Revenue
AU$27.8m
|
CAGR 3-Years
24%
|
CAGR 5-Years
16%
|
CAGR 10-Years
9%
|
Neurotech International Ltd
ASX:NTI
|
Revenue
AU$1.3m
|
CAGR 3-Years
148%
|
CAGR 5-Years
83%
|
CAGR 10-Years
N/A
|
|
ImpediMed Ltd
ASX:IPD
|
Revenue
AU$10.5m
|
CAGR 3-Years
17%
|
CAGR 5-Years
24%
|
CAGR 10-Years
13%
|
|
Cochlear Ltd
ASX:COH
|
Revenue
AU$2.1B
|
CAGR 3-Years
18%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
|
Optiscan Imaging Ltd
ASX:OIL
|
Revenue
AU$1.7m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
34%
|
|
EMvision Medical Devices Ltd
ASX:EMV
|
Revenue
AU$7.1m
|
CAGR 3-Years
93%
|
CAGR 5-Years
70%
|
CAGR 10-Years
N/A
|
See Also
What is Cyclopharm Ltd's Revenue?
Revenue
27.8m
AUD
Based on the financial report for Dec 31, 2023, Cyclopharm Ltd's Revenue amounts to 27.8m AUD.
What is Cyclopharm Ltd's Revenue growth rate?
Revenue CAGR 10Y
9%
Over the last year, the Revenue growth was 11%. The average annual Revenue growth rates for Cyclopharm Ltd have been 24% over the past three years , 16% over the past five years , and 9% over the past ten years .